Basic Information
Vivatides Therapeutics, based on its self-developed extrahepatic delivery technology platform, focuses on the targeted delivery of small nucleic acid drugs to non-liver tissues, aiming to break through the technical bottleneck that traditionally limits small nucleic acid drugs to liver delivery. The core mission is to overcome the delivery of small nucleic acid drugs to extrahepatic tissues through innovative technologies, addressing unmet medical needs.
Vivatides Therapeutics Limited
Hong Kong,China
15~50 people
January 01, 2025
--
--

